Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883114 | PMC |
| http://dx.doi.org/10.1021/acs.analchem.2c04606 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolomic Analysis and Computational Biology Reveal the Potential Metabolic Pathways for Improvement of Fucoxanthin and Eicosapentaenoic Acid (EPA) Biosynthesis in Phaeodactylum tricornutum.
Appl Biochem Biotechnol
January 2025
Plant Morphogenesis and Biochemistry Laboratory, Federal University of Santa Catarina - UFSC, Florianopolis, Santa Catarina, Brazil.
This work aims to provide a basis for the enhancement of fucoxanthin (FCX) and eicosapentaenoic acid (EPA) biosynthesis in the microalga Phaeodactylum tricornutum using metabolomics and computational biology. To achieve this, both targeted (UHPLC and GC-FID) and untargeted (FTIR and NMR) analyses were conducted throughout various stages of cell cultivation. Targeted analyses revealed that EPA concentrations peaked at the end of the logarithmic growth phase, while fucoxanthin levels remained consistent from the onset of this phase through to the stationary phase.
View Article and Find Full Text PDFMetabolomic in severe traumatic brain injury: exploring primary, secondary injuries, diagnosis, and severity.
Crit Care
January 2025
Department of Critical Care Medicine, Cumming School of Medicine, Health Research Innovation Center (HRIC), University of Calgary, Room 4C64, 3280 Hospital Drive N.W., Calgary, AB, T2N 4Z6, Canada.
Background: Traumatic brain injury (TBI) is a major public health concern worldwide, contributing to high rates of injury-related death and disability. Severe traumatic brain injury (sTBI), although it accounts for only 10% of all TBI cases, results in a mortality rate of 30-40% and a significant burden of disability in those that survive. This study explored the potential of metabolomics in the diagnosis of sTBI and explored the potential of metabolomics to examine probable primary and secondary brain injury in sTBI.
View Article and Find Full Text PDFStructural characteristics of a heteropolysaccharide from Ganoderma lucidum and its protective effect against Alzheimer's disease via modulating the microbiota-gut-metabolomics.
Int J Biol Macromol
January 2025
College of Medicine, Jiaxing University, Jiaxing 314001, PR China. Electronic address:
Ganoderma lucidum is a traditional Chinese medicine used to treat Alzheimer's disease (AD), whose main active ingredient is polysaccharides. A heteropolysaccharide named GLPZ-1 was isolated from Ganoderma lucidum. GLPZ-1 (6.
View Article and Find Full Text PDFSynthesis of harmaline N-9 derivatives and investigation of in vitro anticancer activity.
Bioorg Med Chem Lett
January 2025
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488 China. Electronic address:
Harmaline as a natural compound possessed a wide range of pharmacological activities. In this study, 22 novel harmaline-based derivatives were synthesized and screened for in vitro anti-proliferation activity against three cancer cell lines, HCT116, MCF7, and MGC803. The modification site was at the position N-9 of harmaline.
View Article and Find Full Text PDFTwo-Phase Extraction for Comprehensive Analysis of the Plant Metabolome by NMR.
Methods Mol Biol
January 2025
Grupo Metabolômica, Universidade Estadual do Norte Fluminense, Campos dos Goytacazes, RJ, Brazil.
Metabolomics is the area of research, which strives to obtain complete metabolic fingerprints, to detect differences between them and to provide hypothesis to explain those differences (Schripsema J, Dagnino D, Handbook of chemical and biological plant analytical methods. Wiley, New York, 2015). However, obtaining complete metabolic fingerprints is not an easy task.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!